MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 881 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
REDX05358
CAS:<p>REDX05358: Selective pan RAF inhibitor for BRAF/RAS mutant tumors with high affinity, safety, and low paradoxical activation.</p>Fórmula:C26H21ClN4O3Cor e Forma:SolidPeso molecular:472.92KRAS inhibitor-3
CAS:<p>KRAS inhibitor-3 targets WT/oncogenic KRAS; high affinity (KD: 0.28-0.74 μM); disrupts KRAS-Raf interaction.</p>Fórmula:C25H27N5OCor e Forma:SolidPeso molecular:413.51Spiclomazine HCl
CAS:Spiclomazine HCl induced apoptosis in pancreatic cancer cells, which was generally related to cell viability, migration, and invasion.Fórmula:C22H25Cl2N3OS2Cor e Forma:SolidPeso molecular:482.49PF-04880594
CAS:<p>PF-04880594 is a potent and selective RAF inhibitor which inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 exhibits antitumor activity [1].</p>Fórmula:C19H16F2N8Cor e Forma:SolidPeso molecular:394.38KRAS G12C inhibitor 48
<p>KRAS G12C inhibitor 48: potent with IC50 639.91 nM; hampers H358, H23, A549 cell growth with IC50s of 0.796, 6.33, 16.14 µM, respectively.</p>Fórmula:C36H39ClN8O2Cor e Forma:SolidPeso molecular:651.2KRAS G12C inhibitor 31
CAS:<p>KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Cor e Forma:SolidPeso molecular:508.93Nek2-IN-6
CAS:<p>Nek2-IN-6 inhibitor .</p>Fórmula:C33H33F3N6O4SCor e Forma:SolidPeso molecular:666.71L-167307
CAS:<p>L-167307 is a p38 kinase inhibitor.</p>Fórmula:C22H17FN2OSPureza:98%Cor e Forma:SolidPeso molecular:376.45KRAS4b-IN-D14
CAS:<p>KRAS4b-IN-D14 inhibits oncogenic KRAS4b, shrinks tumors, and induces cancer cell apoptosis.</p>Fórmula:C24H24ClN5O4Cor e Forma:SolidPeso molecular:481.93HPK1-IN-15
CAS:<p>HPK1-IN-15 selectively inhibits HPK1, a MAP4K family kinase, potentially aiding in cancer treatment.</p>Fórmula:C24H21ClF3N5Cor e Forma:SolidPeso molecular:471.91KRAS G12D inhibitor 13
CAS:<p>KRAS G12D inhibitor 13 targets KRAS G12D-mediated cancers with potency (WO2021108683A1, cmpd 142).</p>Fórmula:C31H33F2N7O3Cor e Forma:SolidPeso molecular:589.64KRAS G12C inhibitor 42
CAS:<p>KRAS G12C inhibitor 42 targets KRAS G12C for potential cancer therapy. (Patent WO2020146613A1, compound 10)</p>Fórmula:C33H34FN7O2Cor e Forma:SolidPeso molecular:579.67p38-α MAPK-IN-4
CAS:<p>p38-α MAPK-IN-4 (Compound 69) is a selective inhibitor of p38α MAPK, demonstrating potent inhibition with an IC50 of 1.5 μM.</p>Fórmula:C17H13BrN2OCor e Forma:SolidPeso molecular:341.2LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Fórmula:C28H18F4N6O2SCor e Forma:SolidPeso molecular:578.54KRAS G12C inhibitor 39
CAS:<p>KRAS G12C inhibitor 39 effectively targets KRAS G12C, a key protein in cancer research.</p>Fórmula:C37H43N9O2Cor e Forma:SolidPeso molecular:645.8CBS-3595
CAS:<p>CBS-3595: potent p38α MAPK/PDE-4 dual inhibitor, strong anti-inflammatory, low toxicity.</p>Fórmula:C18H17FN4O2SPureza:98%Cor e Forma:SolidPeso molecular:372.42GP17
CAS:<p>GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.</p>Fórmula:C26H21F3N4OCor e Forma:SolidPeso molecular:462.47JNK-1-IN-1
CAS:<p>JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.</p>Fórmula:C24H22N6SCor e Forma:SolidPeso molecular:426.54ADTL-EI1712
CAS:<p>ADTL-EI1712: ERK1/2/5 inhibitor (ERK1 IC50=40.43nM, ERK5=64.5nM), blocks HL-60/MKN74 cell growth, not HeLa; effective in MKN74 mouse model.</p>Fórmula:C22H18Cl2N4O2S2Cor e Forma:SolidPeso molecular:505.44JX 401
CAS:<p>JX 401 is a p38α inhibitor.</p>Fórmula:C21H25NO2SPureza:98%Cor e Forma:SolidPeso molecular:355.49SB 204900
CAS:<p>SB 204900 inhibit the release of histamine and TNF-α from RBL-2H3 cells.</p>Fórmula:C18H17NO2Cor e Forma:SolidPeso molecular:279.33HPK1-IN-29
CAS:<p>"HPK1-IN-29 suppresses HPK1, boosting anti-tumor immunity; potential for immune disease research."</p>Fórmula:C26H18F3N5O2Cor e Forma:SolidPeso molecular:489.45DDO3711
CAS:<p>"DDO3711, a PHORC, links an ASK1 inhibitor to a PP5 activator, inhibiting ASK1 (IC50=164.1 nM), dephosphorylating p-ASK1, and showing anti-cancer potential."</p>Fórmula:C42H41N9O6Cor e Forma:SolidPeso molecular:767.83KRAS G12C inhibitor 29
CAS:<p>KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C23H21ClFN5O2Cor e Forma:SolidPeso molecular:453.98-CPT-2Me-cAMP, sodium salt
CAS:<p>8-CPT-2Me-cAMP sodium activates Epac GEFS, targets Rap1/2, has 2.2 μM EC50 for Epac1, doesn't activate PKA, and prompts Ca2+ release in β-cells.</p>Fórmula:C17H16ClN5NaO6PSCor e Forma:SolidPeso molecular:507.82SCH-53870
CAS:<p>SCH-53870 inhibits p21-hRas nucleotide exchange in vitro.</p>Fórmula:C18H18N2O4SCor e Forma:SolidPeso molecular:358.41KRAS inhibitor-16
CAS:<p>KRAS inhibitor-16 blocks KRAS G12C and p-ERK in cancer cells; potential for pancreatic, colorectal, lung cancer treatment. IC50: 0.457 μM.</p>Fórmula:C20H16Cl2FN3O2SCor e Forma:SolidPeso molecular:452.33SOS1-IN-12
CAS:<p>SOS1-IN-12 is a potent inhibitor of SOS1, acting on SOS1 (Ki: 0.11 nM) and on pERK (IC50: 47 nM).</p>Fórmula:C23H26F3N5Cor e Forma:SolidPeso molecular:429.48MTBT
CAS:<p>MTBT is the proliferation of cancer cells inhibitor. It induces cell cycle arrest and activates p38 MAPK.</p>Fórmula:C14H11NO2S2Cor e Forma:SolidPeso molecular:289.37ARS-2102
CAS:<p>ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research .</p>Fórmula:C28H31ClF2N6O2Cor e Forma:SolidPeso molecular:557.03ERK5-IN-4
CAS:<p>ERK5-IN-4 (34b) is a potent, specific ERK5 inhibitor; IC50: 77 nM full-length, 300 nM ΔTAD in HEK293 cells.</p>Fórmula:C16H11Cl2FN4O2Cor e Forma:SolidPeso molecular:381.19KRAS inhibitor-15
CAS:<p>KRAS inhibitor-15 blocks KRAS G12C and p-ERK in cancer cells; potent against pancreatic and lung cancers. IC50: 0.954 μM (KRAS), 2.03/>33.3 μM (p-ERK).</p>Fórmula:C20H17Cl2FN4OSCor e Forma:SolidPeso molecular:451.34(S)-p38 MAPK Inhibitor III
CAS:<p>(S)-p38 MAPK inhibitor III: a cell-permeable, methylsulfanylimidazole; IC50s: 0.90 µM for p38 MAPK, 0.37 µM TNF-α, 0.044 µM IL-1β.</p>Fórmula:C23H21FN4SCor e Forma:SolidPeso molecular:404.5(R)-PD 0325901CL
CAS:<p>(R)-PD 0325901CL, a PD 0325901CL isomer, is a MEK inhibitor used in cancer research, effective against cancer cells in vitro and in vivo.</p>Fórmula:C16H14ClF2IN2O4Cor e Forma:SolidPeso molecular:498.65RAS inhibitor Abd-7
CAS:<p>Abd-7: potent RAS inhibitor (Kd=51 nM) that blocks RAS-effector PPI, disrupting KRAS, NRAS Q61H, HRAS G12V signaling.</p>Fórmula:C23H25N3O3Cor e Forma:SolidPeso molecular:391.46RAF-IN-1
CAS:<p>RAF-IN-1: strong b/cRAF inhibitor; cRAF IC50=3.8 nM; bRAFwt IC50=36 nM; bRAFV600E IC50=29.4 nM; A375/H358 bRAFV600E GI50=3.4/2.9 nM.</p>Fórmula:C26H22F3N3O4Cor e Forma:SolidPeso molecular:497.47KRAS inhibitor-4
CAS:<p>KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.</p>Fórmula:C30H39ClN8OPureza:98%Cor e Forma:SolidPeso molecular:563.14Anti-inflammatory agent 33
CAS:<p>Agent 33: potent p38α inhibitor, reduces NO, iNOS, COX-2, p-p38α, p-MK2; shows anti-inflammatory effects.</p>Fórmula:C22H15N3O5SCor e Forma:SolidPeso molecular:433.44RSK2-IN-3
CAS:<p>RSK2-IN-3 (Compound 26) is a covalent, reversible inhibitor of RPS6KA3 (RSK2) kinase.</p>Fórmula:C24H26N4O5Cor e Forma:SolidPeso molecular:450.49MLKL-IN-5
CAS:<p>MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .</p>Fórmula:C18H20N6O4SCor e Forma:SolidPeso molecular:416.45HPK1-IN-28
CAS:<p>HPK1-IN-28 inhibits HPK1, boosts anti-tumor immunity, and shows promise in immune disease research per patent WO2021175270A1.</p>Fórmula:C25H22F3N5O4Cor e Forma:SolidPeso molecular:513.47JTP-70902
CAS:<p>JTP-70902 is a protein kinase inhibitor with antineoplastic activity.</p>Fórmula:C24H21BrFN5O5SCor e Forma:SolidPeso molecular:590.42Antifungal agent 46
CAS:<p>Compound 2f (Antifungal Agent 46) is a potent antifungal that inhibits Ras signaling by targeting protein farnesyltransferase [1].</p>Fórmula:C26H28BrF3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:565.43p38 MAP Kinase Inhibitor IV
CAS:<p>p38 MAPK inhibitor IV blocks p38α/β/γ/δ with IC50s 0.13-8.63 μM and stops TNF-α/IL-1β at 22/44 nM in human cells.</p>Fórmula:C12H4Cl6O4SCor e Forma:SolidPeso molecular:456.94KRAS inhibitor-10
CAS:<p>KRAS inhibitor-10: potent, selective KRAS protein blocker; effective in various cancers; oral; tetrahydroisoquinoline class.</p>Fórmula:C30H37N3O5Cor e Forma:SolidPeso molecular:519.63KRAS G12C inhibitor 45
CAS:<p>KRAS G12C inhibitor 45 is a potent KRAS G12C inhibitor .</p>Fórmula:C32H33F2N5O5SCor e Forma:SolidPeso molecular:637.7JNK3 inhibitor-4
CAS:<p>JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.</p>Fórmula:C28H27N7OCor e Forma:SolidPeso molecular:477.56HPK1-IN-17
CAS:<p>HPK1-IN-17 selectively inhibits HPK1, a MAP4Ks family kinase from blood progenitor cells; useful against HPK1-related diseases like cancer.</p>Fórmula:C26H28N6OCor e Forma:SolidPeso molecular:440.54KRAS inhibitor-17
CAS:<p>KRAS inhibitor-17 blocks G12C mutation (IC50: 3.37μM) and p-ERK in MIA PaCA-2 (IC50: 9.25μM). Could target pancreatic, colorectal, lung cancers.</p>Fórmula:C21H18Cl2FN3O2SCor e Forma:SolidPeso molecular:466.36BRAF V600E/CRAF-IN-2
CAS:<p>Potent BRAFV600E/CRAF inhibitor, IC50: 0.888/0.229 μM, induces G0/G1 arrest and apoptosis in HCT-116 cells, potential for cancer research.</p>Fórmula:C30H30F3N5O2Cor e Forma:SolidPeso molecular:549.59KRAS4b-PDEδ stabilizer C19
CAS:<p>KRAS4b-PDEδ stabilizer C19 is a stabilizer of the KRAS4b-PDEδ complex which decreases the proliferation of colorectal cancer cells, and increases apoptosis via</p>Fórmula:C18H20Cl2N2O3Cor e Forma:SolidPeso molecular:383.27SCH 51344
CAS:<p>SCH 51344 inhibits Ras induced malignant transformation. SCH 51344 prevents anchorage-independent growth of oncogene transformed fibroblasts [1].</p>Fórmula:C16H20N4O3Cor e Forma:SolidPeso molecular:316.36LX-3
CAS:<p>LX-3 activates p38 MAPK, enabling expression of genes normally silenced by DNA methylation.</p>Fórmula:C20H13BrN4OSCor e Forma:SolidPeso molecular:437.31KRAS G12C inhibitor 47
CAS:<p>KRAS G12C inhibitor 47 strongly blocks KRAS G12C (IC50: 0.172 μM) and p-ERK in cells; promising for pancreatic, colorectal, lung cancers.</p>Fórmula:C30H28ClFN4O3Cor e Forma:SolidPeso molecular:547.02SOS1-IN-3
CAS:<p>SOS1-IN-3 is an effective inhibitor of SOS1 (son of sevenless homolog 1) (IC50=5 nM). SOS1-IN-3 shows antitumor activity.</p>Fórmula:C21H21F3N4OCor e Forma:SolidPeso molecular:402.41SOS1 activator 1
CAS:<p>SOS1 activator 1 enhances SOS1's GDP-GTP exchange on Ras (Kd: 44 nM).</p>Fórmula:C26H32ClFN6Cor e Forma:SolidPeso molecular:483.026-T-GDP
CAS:<p>6-T-GDP (6-Thioguanosine 5'-diphosphate) is a metabolite of thiopurine. It inhibits the activity of Rac1, thereby reducing the transcription of inflammatory factors and the expression of cell adhesion molecules, which ultimately suppresses leukocyte migration and the occurrence of tissue inflammation.</p>Fórmula:C10H15N5O10P2SCor e Forma:SolidPeso molecular:459.27GDC-0879
CAS:<p>GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well.</p>Fórmula:C19H18N4O2Pureza:99.62%Cor e Forma:SolidPeso molecular:334.37Tpl2-IN-I
CAS:<p>Tpl2-IN-I is an inhibitor of tumour progression locus 2 (Tpl2) kinase.</p>Fórmula:C21H14ClFN6Pureza:98%Cor e Forma:SolidPeso molecular:404.83NSC1011
CAS:NSC1011 is an inhibitor of ras converting enzyme 1 (Rce1).Fórmula:C23H18N2O3Pureza:98%Cor e Forma:SolidPeso molecular:370.4AZD6703 free base
CAS:<p>AZD6703 is a potent, selective and reversible orally bioavailable inhibitor of p38 mitogen-activated protein kinase 14 (MAPK14).</p>Fórmula:C24H27N5O2Cor e Forma:SolidPeso molecular:417.5Kobe2601
CAS:<p>Kobe2601 is a Kobe0065 and Kobe02602 water-soluble analog. It displays inhibitory activity towards Ras-Raf binding.</p>Fórmula:C13H10FN5O4SPureza:98%Cor e Forma:SolidPeso molecular:351.31GSK329
CAS:<p>GSK329 selectively inhibits TNNI3K, showing cardioprotection in ischemic heart models.</p>Fórmula:C19H14Cl2F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:472.25GSK649A
CAS:<p>GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.</p>Fórmula:C15H12ClFN6OSPureza:98%Cor e Forma:SolidPeso molecular:378.81CP-281384
CAS:<p>CP-281384 is a potent, p38alpha-selective inhibitor.</p>Fórmula:C18H14F2N4OPureza:98%Cor e Forma:SolidPeso molecular:340.33RBC6
CAS:<p>RBC6 is an inhibitor of the binding of Ral to its effector RALBP1.</p>Fórmula:C16H14Cl2N4O2Pureza:98%Cor e Forma:SolidPeso molecular:365.21CP-944629
CAS:<p>CP-944629 is a novel, potent, and selective inhibitor of p38alpha.</p>Fórmula:C19H15F3N4OPureza:98%Cor e Forma:SolidPeso molecular:372.34BNC-1
CAS:<p>BNC-1 reduces amyloid in mice, enhances synapses by activating Elk-1.</p>Fórmula:C16H14N2O3Pureza:98%Cor e Forma:SolidPeso molecular:282.29(2Z,3Z)-U0126
CAS:U0126 selectively inhibits MEK1/2, blocks MAPK/ERK signaling, and suppresses Ki-ras-induced cell growth, with IC50s of 72 nM and 58 nM for MEK1/2.Fórmula:C18H16N6S2Cor e Forma:SolidPeso molecular:380.49Migoprotafib
CAS:Migoprotafib (GDC-1971) is a potent and highly selective SHP2 (Src Homology-2 Domain-Containing Phosphatase 2) inhibitor for advanced solid tumours.Fórmula:C25H26N8OCor e Forma:SolidPeso molecular:454.53BSJ-04-122
CAS:<p>BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM & 181 nM, used in cancer research.</p>Fórmula:C15H12ClN5OPureza:97.61%Cor e Forma:SolidPeso molecular:313.74CK1-IN-2
CAS:<p>CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor p38a, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.</p>Fórmula:C17H12FN3O2Pureza:99.31%Cor e Forma:SolidPeso molecular:309.29SR-3306
CAS:<p>SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.</p>Fórmula:C28H26N8OPureza:99.38% - 99.71%Cor e Forma:SolidPeso molecular:490.56GNE-1858
CAS:<p>GNE-1858 inhibits HPK1; IC50: 1.9 nM for wild-type, 1.9 nM (HPK1-TSEE), 4.5 nM (HPK1-SA).</p>Fórmula:C21H26F2N8Pureza:99.36%Cor e Forma:SolidPeso molecular:428.48J30-8
CAS:<p>J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.</p>Fórmula:C17H9ClFN3O2SPureza:99.90%Cor e Forma:SolidPeso molecular:373.79TAK1/MAP4K2 inhibitor 1
CAS:<p>TAK1/MAP4K2 inhibitor 1 (compound 5) is a dual kinase inhibitor of TAK1 and MAP4K2 with IC50 values of 41.1 nM and 18.2 nM, respectively.</p>Fórmula:C29H31F3N6O2Pureza:98%Cor e Forma:SolidPeso molecular:552.59RMM-46
CAS:<p>RMM-46 is a reversible covalent inhibitor with high ligand efficiency and selectivity for MSK/RSK family kinases.</p>Fórmula:C24H26N4O5Pureza:98.89%Cor e Forma:SolidPeso molecular:450.49LY-2584702 hydrochloride
CAS:<p>Ly-2584702 hydrochloride is a p70S6K selective ATP competitive inhibitor with IC50 of 4 nM.In the S6K1 enzyme assay, the IC50 of LY-2584702 was 2 nM.</p>Fórmula:C21H20ClF4N7Pureza:98%Cor e Forma:SolidPeso molecular:481.88MEK inhibitor
CAS:<p>MEK inhibitor is a MEK receptor and cell cycle protein/CDK complex inhibitor with antitumor activity that can be used to study tumor cell proliferation.</p>Fórmula:C26H26N4O2Pureza:97.48%Cor e Forma:SolidPeso molecular:426.51NSC-70220
CAS:<p>SOS1-IN-1 is an inhibitor of SOS1.</p>Fórmula:C22H15NO2Pureza:98%Cor e Forma:SolidPeso molecular:325.36MNK1/2-IN-5
CAS:<p>MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor with anticancer activity and can be used to study solid tumors and hematological malignancies.</p>Fórmula:C17H16N4O2Pureza:98.04%Cor e Forma:SolidPeso molecular:308.33MEK-IN-4
CAS:<p>MEK-IN-4 is a MEK inhibitor that can be used to study inflammatory diseases and cancer.</p>Fórmula:C21H18N4OSPureza:98.35% - 99.16%Cor e Forma:SolidPeso molecular:374.46Nek2-IN-5
CAS:<p>Nek2-IN-5 (NCL00017509) is a potent and selective inhibitor of NIMA-related kinase 2 (Nek2).</p>Fórmula:C15H12N6OPureza:98.11%Cor e Forma:SolidPeso molecular:292.3mSIRK
CAS:<p>mSIRK (G-Protein βγ Binding Peptide) is an ERK1 and ERK2 dual activator that promotes alpha-subunit dissociation.</p>Fórmula:C93H150N20O25Pureza:99.26%Cor e Forma:SolidPeso molecular:1948.31AKP-001
CAS:AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.Fórmula:C21H13ClF2N4O2Pureza:99.50% - 99.92%Cor e Forma:SolidPeso molecular:426.8p38 MAPK Inhibitor
CAS:<p>p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.</p>Fórmula:C20H13ClFN3OPureza:99.91%Cor e Forma:SolidPeso molecular:365.79BI-2852
CAS:<p>BI-2852: nanomolar affinity KRAS switch I/II pocket inhibitor; blocks signaling, halts KRAS mutant cell growth.</p>Fórmula:C31H28N6O2Pureza:98.98%Cor e Forma:SolidPeso molecular:516.59p38α inhibitor 4
CAS:p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.Fórmula:C14H7F6N3OPureza:99.69%Cor e Forma:SolidPeso molecular:347.215MKK7-COV-9
CAS:MKK7-COV-9 is an MKK7 inhibitor that inhibits MKK7-induced protein-protein interactions and interrupts the activation of primary B cells in response to LPS.Fórmula:C18H16N4O2Pureza:99.73% - 99.83%Cor e Forma:SolidPeso molecular:320.35RMC-0331
CAS:<p>RMC-0331 (RM-023) is an oral SOS1 inhibitor with potential to block RAS activation and anticancer properties.</p>Fórmula:C22H25ClF3N5O3Pureza:99.81%Cor e Forma:SolidPeso molecular:499.91NMDAR/TRPM4-IN-2
CAS:<p>Potent NMDAR/TRPM4-IN-2 blocks NMDAR/TRPM4, protects brain and retinal neurons, and prevents mitochondrial dysfunction with an IC50 of 2.1 μM.</p>Fórmula:C11H19BrCl2N2Pureza:98.77%Cor e Forma:SolidPeso molecular:330.092EO-1606
CAS:<p>EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.</p>Fórmula:C21H17ClFNOPureza:98.28% - 98.84%Cor e Forma:SolidPeso molecular:353.82ZINC12409120
CAS:<p>ZINC12409120 (R-4584) is a selective ERK inhibitor.ZINC12409120 inhibits ERK with an IC50 of 5.0 μM.ZINC12409120 inhibits ERK activity by interfering with FGF23</p>Fórmula:C20H16N4O2Pureza:99.71% - 99.95%Cor e Forma:SolidPeso molecular:344.37GSK2008607
CAS:<p>GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.</p>Fórmula:C31H28F3N7O3S2Pureza:99.36%Cor e Forma:SolidPeso molecular:667.72JNK-IN-11
CAS:<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>Fórmula:C12H11NO3S2Pureza:98.82%Cor e Forma:SolidPeso molecular:281.35DS12881479
CAS:<p>DS12881479 can be used in cancer research which is a potent and selective inhibitor of Mnk1(IC 50 =21 nM) [1].</p>Fórmula:C16H19N3OSPureza:99.85%Cor e Forma:SolidPeso molecular:301.41SOS1-IN-15
CAS:<p>SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.</p>Fórmula:C28H27F3N6O2Pureza:98.32%Cor e Forma:SolidPeso molecular:536.548UR13870
CAS:<p>UR-13870 (Org 48762-0) is a p38 MAPK inhibitor that prevents bone damage in collagen-induced arthritis in mice.</p>Fórmula:C24H16F2N4Pureza:99.18% - >99.99%Cor e Forma:SolidPeso molecular:398.41(E)-GABAB receptor antagonist 1
CAS:<p>(E)-GABAB antagonist 1 inhibits GABA IP3 production, with an IC50 of 37.9 μM and acts as a selective negative modulator.</p>Fórmula:C18H24O4Pureza:98.09%Cor e Forma:SolidPeso molecular:304.38ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Fórmula:C18H12N6OCor e Forma:SolidPeso molecular:328.33
